​Rheumatoid Arthritis
  1. Chen SK, Liao KP, Liu J, Kim SC. Risk of Hospitalized Infection and Initiation of Abatacept versus TNF Inhibitors among Patients with Rheumatoid Arthritis: a Propensity Score-Matched Cohort Study. Arthritis Care Res (Hoboken). 2018 Dec 20. PMID
  2. ​Kim SC, Feldman S, Moscicki AB. Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention. Rheumatology (Oxford). 2018 07 01; 57(suppl_5):v26-v33. PMID: 30137592.
  3. Yu Z, Kim SC, Vanni K, Huang J, Desai R, Murphy SN, Solomon DH, Liao KP. Association between inflammation and systolic blood pressure in RA compared to patients without RA. Arthritis Res Ther. 2018 Jun 01; 20(1):107. PMID: 29855349.
  4. Kang EH, Liao KP, Kim SC. Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis. Curr Rheumatol Rep. 2018 May 30; 20(7):42. PMID: 29846814.
  5. Jin Y, Kang EH, Brill G, Desai RJ, Kim SC. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. J Rheumatol. 2018 Aug; 45(9):1240-1248. PMID: 29764964.
  6. Lee MP, Lii J, Jin Y, Desai RJ, Solomon DH, Merola JF, Kim SC. Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015. Arthritis Care Res (Hoboken). 2018 May; 70(5):791-796. PMID: 28804988.
  7. Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2018 Mar 22. PMID: 29673963.
  8. Kang EH, Jin Y, Brill G, Lewey J, Patorno E, Desai RJ, Kim SC. Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study. J Am Heart Assoc. 2018 Jan 24; 7(3). PMID: 29367417.
  9. Desai RJ, Franklin JM, Kim SC. Alendronate and Hip Fracture in Patients Using Glucocorticoids. JAMA. 2017 11 07; 318(17):1711-1712. PMID: 29114826.
  10. Desai RJ, Solomon DH, Jin Y, Liu J, Kim SC. Temporal Trends in Use of Biologic DMARDs for Rheumatoid Arthritis in the United States: A Cohort Study of Publicly and Privately Insured Patients. J Manag Care Spec Pharm. 2017 Aug; 23(8):809-814. PMID: 28737992.
  11. Jin Y, Desai RJ, Liu J, Choi NK, Kim SC. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis. Arthritis Res Ther. 2017 07 05; 19(1):159. PMID: 28679392.
  12. Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis Rheumatol. 2017 06; 69(6):1154-1164. PMID: 28245350.
  13.  Feldman CH, Marty FM, Winkelmayer WC, Guan H, Franklin JM, Solomon DH, Costenbader KH, Kim SC. Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. Arthritis Rheumatol. 2017 02; 69(2):387-397. PMID: 27589220.
  14. Kim SC, Schneeweiss S, Liu J, Karlson EW, Katz JN, Feldman S, Solomon DH. Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study. Arthritis Rheumatol. 2016 09; 68(9):2106-13. PMID: 27015113; PMCID: PMC5001884 
  15. Desai RJ, Solomon DH, Schneeweiss S, Danaei G, Liao KP, Kim SC. Tumor Necrosis Factor-a Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. Epidemiology. 2016 May; 27(3):414-22. PMID: 26808597.
  16.  Desai RJ, Huybrechts KF, Bateman BT, Hernandez-Diaz S, Mogun H, Gopalakrishnan C, Patorno E, Kim SC. Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. Arthritis Rheumatol. 2016 05; 68(5):1183-9. PMID: 26606742; PMCID: PMC4848128
  17. Solomon DH, Kim SC. Potential confounding in colchicine and cardiovascular disease study. Ann Rheum Dis. 2016 May; 75(5):e27. PMID: 26873269.
  18. Liao KP, Liu J, Lu B, Solomon DH, Kim SC. Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients. Arthritis Rheumatol. 2015 May; 67(8):2004-10. PMID: 25917955; PMCID: PMC4418211.
  19. Desai RJ, Solomon DH, Weinblatt ME, Shadick N, Kim SC. An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. Arthritis Res Ther. 2015 Apr 13; 17:83. PMID: 25880932; PMCID: PMC4394559.
  20. Desai RJ, Eddings W, Liao KP, Solomon DH, Kim SC. Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study. Arthritis Care Res (Hoboken). 2015 Apr; 67(4):457-66. PMID: 25302481; PMCID: PMC4751079.
  21. Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015 Jul; 11(7):437-41. PMID: 25800216; PMCID: PMC4486631.
  22. Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, Clowse M, Curtis JR, Dao K, Hankins GD, Koren G, Kim SC, Lapteva L, Mahadevan U, Moore T, Nolan M, Ren Z, Sammaritano LR, Seymour S, Weisman MH. Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res (Hoboken). 2015 Mar; 67(3):313-25. PMID: 25385050.
  23. Kim SC, Landon JE, Lee YC. Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia. Arthritis Res Ther. 2015 Jan 28; 17:18. PMID: 25627453; PMCID: PMC4343277.
  24. Kim SC, Solomon DH, Liu J, Franklin JM, Glynn RJ, Schneeweiss S. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med. 2015 May; 128(5):539.e7-17. PMID: 25534420; PMCID: PMC4414700.
  25. Polinski JM, Brookhart MA, Ayanian JZ, Katz JN, Kim SC, Lii J, Tonner C, Yelin E, Solomon DH. Relationships between driving distance, rheumatoid arthritis diagnosis, and disease-modifying antirheumatic drug receipt. Arthritis Care Res (Hoboken). 2014 Nov; 66(11):1634-43. PMID: 24664991; PMCID: PMC4175286.
  26. Gillet VG, Solomon DH, Shadick NA, Weinblatt ME, Iannaccone CK, Feldman S, Kim SC. Behavioral and clinical factors associated with self-reported abnormal Papanicolaou tests in rheumatoid arthritis. J Womens Health (Larchmt). 2014 Sep; 23(9):771-6. PMID: 25203494; PMCID: PMC4158949.
  27. Solomon DH, Tonner C, Lu B, Kim SC, Ayanian JZ, Brookhart MA, Katz JN, Yelin E. Predictors of stopping and starting disease-modifying antirheumatic drugs for rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Aug; 66(8):1152-8. PMID: 24470443; PMCID: PMC4112169.
  28. Kim SC, Schneeweiss S, Glynn RJ, Doherty M, Goldfine AB, Solomon DH. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis. 2015 Nov; 74(11):1968-75. PMID: 24919467; PMCID: PMC4263684 
  29. Kim SC, Glynn RJ, Giovannucci E, Hernández-Díaz S, Liu J, Feldman S, Karlson EW, Schneeweiss S, Solomon DH. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015 Jul; 74(7):1360-7. PMID: 24618265; PMCID: PMC4161656.
  30. Kim SC, Hernandez-Diaz S. Editorial: Safety of immunosuppressive drugs in pregnant women with systemic inflammatory diseases. Arthritis Rheumatol. 2014 Feb; 66(2):246-9. PMID: 24504795; PMCID: PMC3994991.
  31. Kim SC, Landon JE, Solomon DH. Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin. Arthritis Care Res (Hoboken). 2013 Nov; 65(11):1813-9. PMID: 23861291; PMCID: PMC4059353.
  32. Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Oct; 65(10):1600-7. PMID: 23666917
  33. Kim SC, Yelin E, Tonner C, Solomon DH. Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009. Arthritis Care Res (Hoboken). 2013 Sep; 65(9):1529-33. PMID: 23463543
  34. Kim SC, Liu J, Solomon DH. The risk of atrial fibrillation in patients with rheumatoid arthritis. Ann Rheum Dis. 2014 Jun; 73(6):1091-5. PMID: 23606703; 
  35. Kim SC, Schneeweiss S, Myers JA, Liu J, Solomon DH. No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population. Arthritis Rheum. 2012 Oct; 64(10):3076-82. PMID: 22782529
  36. Kim SY, Schneeweiss S, Liu J, Solomon DH. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res. 2012 Apr; 27(4):789-96. PMID: 22162140
  37. Kim SY, Solomon DH. Use of administrative claims data for comparative effectiveness research of rheumatoid arthritis treatments. Arthritis Res Ther. 2011; 13(5):129. PMID: 21996148
  38. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, Solomon DH. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther. 2011 Feb 23; 13(1):R32. PMID: 21345216; PMCID: PMC3241376.
  39. Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, Solomon DH. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther. 2010; 12(4):R154. PMID: 20682035; PMCID: PMC2945054.
  40. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol. 2010 Mar; 6(3):165-74. PMID: 20142812; PMCID: PMC3155180.
​Gout
  1. Zhang M, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T, Kim SC. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. Circulation. 2018 Sep 11; 138(11):1116-1126. PMID: 29899013.
  2. Kim SC, Neogi T, Kang EH, Liu J, Desai RJ, Zhang M, Solomon DH. Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout. J Am Coll Cardiol. 2018 Mar 06; 71(9):994-1004. PMID: 29496000.
  3. Desai RJ, Franklin JM, Spoendlin-Allen J, Solomon DH, Danaei G, Kim SC. An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. PLoS One. 2018; 13(2):e0193622. PMID: 29489919.
  4. Kim SC, Shah NR, Rogers JR, Bibbo CF, Di Carli MF, Solomon DH. Assessment of coronary vascular function with cardiac PET in relation to serum uric acid. PLoS One. 2018; 13(2):e0192788. PMID: 29438436.​
  5. Kim SC, Paik JM, Liu J, Curhan GC, Solomon DH. Gout and the Risk of Non-vertebral Fracture. J Bone Miner Res. 2017 Feb; 32(2):230-236. PMID: 27541696.
  6. MacFarlane LA, Liu CC, Solomon DH, Kim SC. Validation of claims-based algorithms for gout flares. Pharmacoepidemiol Drug Saf. 2016 07; 25(7):820-6. PMID: 27230083.
  7. Solomon DH, Kim SC. Response to: 'Effects of colchicine on risk of cardiovascular events among patients with gout: as evidence accrues, is it time for a randomized trial?' by Giannopoulos and Deftereos. Ann Rheum Dis. 2016 May; 75(5):e29. PMID: 26929220.
  8. Solomon DH, Liu CC, Kuo IH, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis. 2016 09; 75(9):1674-9. PMID: 26582823.
  9. Kim SC, Liu J, Solomon DH. Risk of incident atrial fibrillation in gout: a cohort study. Ann Rheum Dis. 2016 08; 75(8):1473-8. PMID: 26324846.
  10. Kesselheim AS, Franklin JM, Kim SC, Seeger JD, Solomon DH. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. J Gen Intern Med. 2015 Nov; 30(11):1633-8. PMID: 25855479; 
  11. Kim SC, Schneeweiss S, Choudhry N, Liu J, Glynn RJ, Solomon DH. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015 Jun; 128(6):653.e7-653.e16. PMID: 25660249
  12. Kim SC, Liu J, Solomon DH. Risk of incident diabetes in patients with gout: a cohort study. Arthritis Rheumatol. 2015 Jan; 67(1):273-80. PMID: 25332119; 
  13. MacFarlane LA, Kim SC. Gout: a review of nonmodifiable and modifiable risk factors. Rheum Dis Clin North Am. 2014 Nov; 40(4):581-604. PMID: 25437279;
  14. Kim SC, Schmidt BM, Franklin JM, Liu J, Solomon DH, Schneeweiss S. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. Arthritis Care Res (Hoboken). 2013 Dec; 65(12):2008-14. PMID: 23861232
  15. Kim SC, Newcomb C, Margolis D, Roy J, Hennessy S. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. Arthritis Care Res (Hoboken). 2013 Apr; 65(4):578-84. PMID: 22899369; 
​Biosimilars
  1. Desai RJ, Kim SC, Curtis JR, Bosco JLF, Eichelberger B, Barr CE, Lockhart CM, Bradbury BD, Clewell J, Cohen HP, Gagne JJ. Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. Pharmacoepidemiol Drug Saf. 2019 Jul 12. PMID: 31298463.
  2. Chingcuanco F, Segal JB, Kim SC, Alexander GC. Bioequivalence of Biosimilar Tumor Necrosis Factor-a Inhibitors Compared With Their Reference Biologics: A Systematic Review. Ann Intern Med. 2016 Oct 18; 165(8):565-574. PMID: 27479870.
  3. Kim SC, Choi NK, Lee J, Kwon KE, Eddings W, Sung YK, Ji Song H, Kesselheim AS, Solomon DH. Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea. Arthritis Rheumatol. 2016 05; 68(5):1076-9. PMID: 26662931
Opioids
  1. Jin Y, Solomon DH, Franklin PD, Lee YC, Lii J, Katz JN, Kim SC. Patterns of prescription opioid use before total hip and knee replacement among US Medicare enrollees. Osteoarthritis Cartilage. 2019 Jun 26. PMID: 31251985.
  2. Chen SK, Feldman CH, Brill G, Lee YC, Desai RJ, Kim SC. Use of prescription opioids among patients with rheumatic diseases compared to patients with hypertension in the USA: a retrospective cohort study. BMJ Open. 2019 Jun 19; 9(6):e027495. PMID: 31221884.
  3. Desai RJ, Jin Y, Franklin PD, Lee YC, Bateman BT, Lii J, Solomon DH, Katz JN, Kim SC. Association of geography and access to healthcare providers with long term prescription opioid use in Medicare patients with severe osteoarthritis: A cohort study. Arthritis Rheumatol. 2019 Jan 28. PMID: 30688044.
  4. Kim SC, Choudhry N, Franklin JM, Bykov K, Eikermann M, Lii J, Fischer MA, Bateman BT. Patterns and predictors of persistent opioid use following hip or knee arthroplasty. Osteoarthritis Cartilage. 2017 09; 25(9):1399-1406. PMID: 28433815.
​

​Osteoporosis
  1. Rishi J. Desai, Mufaddal Mahesri, Younathan Abdia, Julie Barberio, Angela Tong, Dongmu Zhang, Panagiotis Mavros, Seoyoung C. Kim, Jessica M. Franklin. Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis. JAMA Network Open. 2018; 3(1):e180826.
  2. Yu EW, Lee MP, Landon JE, Lindeman KG, Kim SC. Fracture Risk After Bariatric Surgery: Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding. J Bone Miner Res. 2017 Jun; 32(6):1229-1236. PMID: 28251687.
  3. Kim SC, Choudhry N, Franklin JM, Bykov K, Eikermann M, Lii J, Fischer MA, Bateman BT. Patterns and predictors of persistent opioid use following hip or knee arthroplasty. Osteoarthritis Cartilage. 2017 09; 25(9):1399-1406. PMID: 28433815.
  4. Choi NK, Solomon DH, Tsacogianis TN, Landon JE, Song HJ, Kim SC. Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. J Bone Miner Res. 2017 Mar; 32(3):611-617. PMID: 27736041.
  5. Kim SC, Kim DH, Mogun H, Eddings W, Polinski JM, Franklin JM, Solomon DH. Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture. J Bone Miner Res. 2016 08; 31(8):1536-40. PMID: 26969902.
  6. Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC. Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One. 2015; 10(4):e0122646. PMID: 25884398
  7. Kim SC, Kim MS, Sanfélix-Gimeno G, Song HJ, Liu J, Hurtado I, Peiró S, Lee J, Choi NK, Park BJ, Avorn J. Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med. 2015 May; 128(5):519-26.e1. PMID: 25660252
  8. Xie J, Tong A, Kim SC. Patterns of bisphosphonates utilization in patients under age 45 in a large cohort of commercial insurance beneficiaries in the United States. PLoS One. 2015; 10(1):e0115091. PMID: 25611596
  9. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013 Aug; 28(8):1729-37. PMID: 23408697
  10. Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2011 May; 26(5):993-1001. PMID: 21542002
  11. Kim SY, Kim MJ, Cadarette SM, Solomon DH. Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Res Ther. 2010; 12(1):R30. PMID: 20170505 
​Inflammatory Bowel Disease
  1. Desai RJ, Gagne JJ, Lii J, Liu J, Friedman S, Kim SC. Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-a inhibitors or nonbiologic agents: a cohort study. CMAJ. 2017 Nov 27; 189(47):E1438-E1447. PMID: 29180383.
  2. Desai RJ, Bateman BT, Huybrechts KF, Patorno E, Hernandez-Diaz S, Park Y, Dejene SZ, Cohen J, Mogun H, Kim SC. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ. 2017 Mar 06; 356:j895. PMID: 28264814.
​Health Services Research
  1. Kim SY, Solomon DH, Liu J, Chang CL, Daniel GW, Schneeweiss S. Accuracy of identifying neutropenia diagnoses in outpatient claims data. Pharmacoepidemiol Drug Saf. 2011 Jul; 20(7):709-13. PMID: 21567653; 
  2. Kim SY, Solomon DH. Pharmacotherapy: comparative safety of nonsteroidal anti-inflammatory drugs. Nat Rev Cardiol. 2011 Apr; 8(4):193-5.  PMCID: PMC3725754.
Other
  1. Bermas BL, Kim SC, Huybrechts K, Mogun H, Hernandez-Diaz S, Bateman BT, Desai RJ. Trends in use of hydroxychloroquine during pregnancy in systemic lupus erythematosus patients from 2001 to 2015. Lupus. 2018 Jan 01; 961203317749046. PMID: 29301469.
  2. Feldman CH, Liu J, Feldman S, Solomon DH, Kim SC. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs. Lupus. 2017 Jun; 26(7):682-689. PMID: 27799438.
  3. Desai RJ, Solomon DH, Shadick N, Iannaccone C, Kim SC. Identification of smoking using Medicare data--a validation study of claims-based algorithms. Pharmacoepidemiol Drug Saf. 2016 Apr; 25(4):472-5. PMID: 26764576; 
  4. Najafzadeh M, Kim SC, Patterson C, Schneeweiss S, Katz JN, Brick GW, Ready JE, Polinski JM, Patorno E. Patients' perception about risks and benefits of antithrombotic treatment for the prevention of venous thromboembolism (VTE) after orthopedic surgery: a qualitative study. BMC Musculoskelet Disord. 2015 Oct 26; 16:319. PMID: 26503220; 
  5. Feldman CH, Hiraki LT, Winkelmayer WC, Marty FM, Franklin JM, Kim SC, Costenbader KH. Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol. 2015 Jun; 67(6):1577-85. PMID: 25772621
  6. Feldman CH, Hiraki LT, Lii H, Seeger JD, Kim SC. Human papillomavirus vaccine uptake among individuals with systemic inflammatory diseases. PLoS One. 2015; 10(2):e0117620. PMID: 25692470; 
  7. Kim SC, Gillet VG, Feldman S, Lii H, Toh S, Brown JS, Katz JN, Solomon DH, Schneeweiss S. Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer. Pharmacoepidemiol Drug Saf. 2013 Nov; 22(11):1239-44. PMID: 24027140.
  8. Desai RJ, Thaler KJ, Mahlknecht P, Gartlehner G, McDonagh MS, Mesgarpour B, Mazinanian A, Glechner A, Gopalakrishnan C, Hansen RA. Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review. Arthritis Care Res (Hoboken) 2016;68(8):1078-88
  9. Desai RJ, Solomon DH. Use of large healthcare databases for rheumatology clinical research. Curr Opin Rheumatol 2017;29(2):138-143
  10. Desai RJ, Mahesri M, Gagne JJ, Hurley E, Tong A, Chitnis T, Minden S, Spettell CM, Matlin OS, Shrank WH, Choudhry NK. Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis. J Manag Care Spec Pharm 2019;25(1):113-121.